细胞周期蛋白依赖性激酶4/6抑制剂：从静止到衰老 - Suppr

CDK4/6 inhibitor: from quiescence to senescence.

作者信息

Yoshida Akihiro, Diehl J Alan

机构信息

Department of Biochemistry and Molecular Biology, Hollings Cancer Center, The Medical University of South Carolina, SC, USA.

出版信息

Oncoscience. 2015 Oct 20;2(11):896-7. doi: 10.18632/oncoscience.256. eCollection 2015.

DOI:10.18632/oncoscience.256

PMID:26697514

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4675777/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4208/4675777/a8dddfade241/oncoscience-02-0896-g001.jpg

相似文献

CDK4/6 inhibitor: from quiescence to senescence.

Oncoscience. 2015 Oct 20;2(11):896-7. doi: 10.18632/oncoscience.256. eCollection 2015.

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.

Oncotarget. 2015 Apr 10;6(10):8226-43. doi: 10.18632/oncotarget.3364.

Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.

Mol Cell Oncol. 2017 Nov 7;5(1):e1384882. doi: 10.1080/23723556.2017.1384882. eCollection 2018.

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence.

Oncogene. 2018 Sep;37(37):5066-5078. doi: 10.1038/s41388-018-0332-y. Epub 2018 May 23.

ATRX is a regulator of therapy induced senescence in human cells.

Nat Commun. 2017 Aug 30;8(1):386. doi: 10.1038/s41467-017-00540-5.

Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.

Mol Cancer Res. 2017 Mar;15(3):237-249. doi: 10.1158/1541-7786.MCR-16-0319. Epub 2016 Dec 30.

The cell fate: senescence or quiescence.

Mol Biol Rep. 2016 Nov;43(11):1213-1220. doi: 10.1007/s11033-016-4065-0. Epub 2016 Aug 24.

Raman and infrared spectroscopy reveal that proliferating and quiescent human fibroblast cells age by biochemically similar but not identical processes.

PLoS One. 2018 Dec 3;13(12):e0207380. doi: 10.1371/journal.pone.0207380. eCollection 2018.

CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus.

Cancer Res. 2005 Mar 15;65(6):2199-206. doi: 10.1158/0008-5472.CAN-04-1526.

Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.

Am J Surg Pathol. 2012 Mar;36(3):462-9. doi: 10.1097/PAS.0b013e3182417330.

引用本文的文献

Inhibition of glutaminase elicits senolysis in therapy-induced senescent melanoma cells.

Cell Death Dis. 2024 Dec 18;15(12):902. doi: 10.1038/s41419-024-07284-3.

Senescence of Tumor Cells in Anticancer Therapy-Beneficial and Detrimental Effects.

Int J Mol Sci. 2022 Sep 21;23(19):11082. doi: 10.3390/ijms231911082.

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells.

Front Oncol. 2022 Jul 22;12:942341. doi: 10.3389/fonc.2022.942341. eCollection 2022.

circACTA2 mediates Ang II-induced VSMC senescence by modulation of the interaction of ILF3 with CDK4 mRNA.

Aging (Albany NY). 2021 Apr 22;13(8):11610-11628. doi: 10.18632/aging.202855.

CSB promoter downregulation via histone H3 hypoacetylation is an early determinant of replicative senescence.

Nat Commun. 2019 Dec 6;10(1):5576. doi: 10.1038/s41467-019-13314-y.

STK11 is required for the normal program of ciliated cell differentiation in airways.

Cell Discov. 2019 Jul 16;5:36. doi: 10.1038/s41421-019-0104-z. eCollection 2019.

Stilbene Compounds Inhibit Tumor Growth by the Induction of Cellular Senescence and the Inhibition of Telomerase Activity.

Int J Mol Sci. 2019 Jun 2;20(11):2716. doi: 10.3390/ijms20112716.

The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.

Nucleic Acids Res. 2019 May 7;47(8):3921-3936. doi: 10.1093/nar/gkz127.

Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma.

Pathol Oncol Res. 2020 Apr;26(2):727-734. doi: 10.1007/s12253-019-00603-6. Epub 2019 Feb 8.

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.

Oncotarget. 2018 Feb 26;9(21):15658-15672. doi: 10.18632/oncotarget.24585. eCollection 2018 Mar 20.

本文引用的文献

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.

Oncotarget. 2015 Apr 10;6(10):8226-43. doi: 10.18632/oncotarget.3364.

A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells.

Cancer Cell. 2011 Nov 15;20(5):620-34. doi: 10.1016/j.ccr.2011.10.001.

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

Mol Cancer Ther. 2007 Mar;6(3):918-25. doi: 10.1158/1535-7163.MCT-06-0613.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

Mol Cancer Ther. 2004 Nov;3(11):1427-38.

CDK inhibitors: positive and negative regulators of G1-phase progression.

Genes Dev. 1999 Jun 15;13(12):1501-12. doi: 10.1101/gad.13.12.1501.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

CDK4/6 inhibitor: from quiescence to senescence.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献